Posted by Michael Wonder on 16 Nov 2016
Proposal to list oral betaine for rare disorder
16 November 2016 - PHARMAC is seeking feedback on a proposal to list betaine (Cystadane) resulting from a provisional agreement between Emerge Health and PHARMAC.
The provisional agreement is the seventh that PHARMAC has reached with a bidder in a Request for Proposals we ran in 2014, related to the supply of medicines for rare disorders.
In summary, this proposal would result in betaine (Cystadane) being funded in the community under Special Authority criteria, and in DHB hospitals subject to restrictions, for the treatment of homocystinuria.
Listing in the Pharmaceutical Schedule would occur after any Medsafe approval of the pharmaceutical.
